Charles W. Newton
CIK: 0001866219
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Aug 18, 2026KROS
Keros Therapeutics, Inc.
Sale(S)Direct551 shares at avg. $10.30$6K - Jun 18, 2026NVAX
NOVAVAX INC
Award(A)DirectRestricted Stock Units
14.2K shares- - Jun 18, 2026NVAX
NOVAVAX INC
Award(A)DirectStock Option (Right to Buy)
21.3K shares- - Jun 11, 2026KROS
Keros Therapeutics, Inc.
Sale(S)Direct550 shares at avg. $10.04$6K - Jun 5, 2026CHRS
Coherus Oncology, Inc.
Award(A)Direct30K shares- - Apr 25, 2026NVAX
NOVAVAX INC
Exercise(M)Direct9.5K shares- - Mar 9, 2026KROS
Keros Therapeutics, Inc.
Award(A)Direct13.2K shares- - Aug 21, 2025LYEL
Lyell Immunopharma, Inc.
Sale(S)Direct1.5K shares at avg. $10.54$15K - Aug 20, 2025LYEL
Lyell Immunopharma, Inc.
Award(A)Direct8K shares- - Aug 12, 2025LYEL
Lyell Immunopharma, Inc.
Sale(S)Direct136 shares at avg. $10.34$1K - Aug 11, 2025LYEL
Lyell Immunopharma, Inc.
Sale(S)Direct131 shares at avg. $10.53$1K - Jun 12, 2025CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
112K shares- - May 13, 2025TSVT
2seventy bio, Inc.
Disposition(D)Direct17.1K shares- - May 13, 2025TSVT
2seventy bio, Inc.
Tender Offer(U)Direct5.5K shares- - Apr 25, 2025NVAX
NOVAVAX INC
Award(A)DirectStock Option (Right to buy)
42.8K shares- - Apr 25, 2025NVAX
NOVAVAX INC
Award(A)DirectRestricted Stock Units
28.6K shares- - Mar 17, 2025LYEL
Lyell Immunopharma, Inc.
Purchase(P)Indirect200K shares at avg. $0.56$112K - Feb 10, 2025LYEL
Lyell Immunopharma, Inc.
Award(A)Direct112.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 18, 2026 |  KROS Keros Therapeutics, Inc. | Sale(S) | 551 | $10.30 | $5,675 | Direct |
| Jun 18, 2026 |  NVAX NOVAVAX INC | Award(A) Restricted Stock Units | 14,180 | - | - | Direct |
| Jun 18, 2026 | NVAX NOVAVAX INC | Award(A) Stock Option (Right to Buy) | 21,270 | - | - | Direct |
| Jun 11, 2026 | KROS Keros Therapeutics, Inc. | Sale(S) | 550 | $10.04 | $5,522 | Direct |
| Jun 5, 2026 |  CHRS Coherus Oncology, Inc. | Award(A) | 30,000 | - | $0 | Direct |
| Apr 25, 2026 | NVAX NOVAVAX INC | Exercise(M) | 9,520 | - | $0 | Direct |
| Mar 9, 2026 | KROS Keros Therapeutics, Inc. | Award(A) | 13,215 | - | $0 | Direct |
| Aug 21, 2025 |  LYEL Lyell Immunopharma, Inc. | Sale(S) | 1,453 | $10.54 | $15,320 | Direct |
| Aug 20, 2025 | LYEL Lyell Immunopharma, Inc. | Award(A) | 8,000 | - | - | Direct |
| Aug 12, 2025 | LYEL Lyell Immunopharma, Inc. | Sale(S) | 136 | $10.34 | $1,406 | Direct |
| Aug 11, 2025 | LYEL Lyell Immunopharma, Inc. | Sale(S) | 131 | $10.53 | $1,379 | Direct |
| Jun 12, 2025 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 112,000 | - | - | Direct |
| May 13, 2025 |  TSVT 2seventy bio, Inc. | Disposition(D) | 17,092 | - | - | Direct |
| May 13, 2025 | TSVT 2seventy bio, Inc. | Tender Offer(U) | 5,533 | - | - | Direct |
| Apr 25, 2025 | NVAX NOVAVAX INC | Award(A) Stock Option (Right to buy) | 42,840 | - | - | Direct |
| Apr 25, 2025 | NVAX NOVAVAX INC | Award(A) Restricted Stock Units | 28,560 | - | - | Direct |
| Mar 17, 2025 | LYEL Lyell Immunopharma, Inc. | Purchase(P) | 200,000 | $0.56 | $111,620 | Indirect |
| Feb 10, 2025 | LYEL Lyell Immunopharma, Inc. | Award(A) | 112,500 | - | - | Direct |
1-18 of 18 transactions
About Newton Charles W.
Newton Charles W. (SEC CIK 0001866219) files insider reports with the SEC as Director of Keros Therapeutics, Inc. (KROS), Director of NOVAVAX INC (NVAX) and Director of Coherus Oncology, Inc. (CHRS). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 15 ownership filings by Newton Charles W. (2 Form 3, 13 Form 4), filed between Feb 26, 2025 and Aug 20, 2026. Those filings report 18 transactions, from Feb 10, 2025 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Newton Charles W.'s filings is in LEXINGTON, MA.
Recent filings by Newton Charles W.
- Aug 18, 2026: Open-market sale of KROS shares (Form 4, code S).
- Jun 18, 2026: Grants or awards of NVAX derivative securities (2 lines, Form 4, code A).
- Jun 11, 2026: Open-market sale of KROS shares (Form 4, code S).
- Jun 5, 2026: Grant or award of CHRS shares (Form 4, code A).
- Apr 25, 2026: Option exercise of NVAX shares (Form 4, code M).
Other insiders filing for Keros Therapeutics, Inc. (KROS)
- Tanini Annita, Corp. Controller & VP, Finance
- Lerner Lorena Raquel, Chief Scientific Officer
- Cho Esther, Chief Legal Officer
- BIENAIME JEAN JACQUES, Director
- Prener Anne, Director
- Farzan Nima, Director